Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure
Glaucoma, Angle-closure, Primary, Acute
About this trial
This is an interventional prevention trial for Glaucoma, Angle-closure, Primary, Acute
Eligibility Criteria
Inclusion Criteria:
• patients with APAC who present to the centre not later than 7 days from the initiation of the attack.
- the presence of at least two of the following symptoms: ocular or periocular pain, nausea or vomiting or both, and an antecedent history of blurring of vision with haloes;
- a presenting intraocular pressure of at least 28 mm Hg on Goldmann applanation tonometry;
- the presence of at least three of the following signs: conjunctival injection, corneal epithelial oedema, middilated unreactive pupil, and shallow anterior chamber;
- the presence of an occludable angle in the affected eye on gonioscopy;
- Age more than 21 years.
- Informed consent
Exclusion Criteria:
• evidence of a prior acute angle closure attack (the presence of iris whorling, focal iris atrophy, or glaucomflecken with a history of an acute red eye and decreased vision). This will not include senile iris and sphincter atrophy);
- Pre-existing chronic angle closure glaucoma in the eye with APAC
- secondary causes of angle closure like subluxed lens, uveitis, trauma and neovascular glaucoma;
- cataract that is deemed significant enough to require surgery during the course of the trial or that makes field testing or optic disc imaging not technically possible- visual acuity less than 6/36 due to any type of cataract;
- corneal abnormalities, media opacities, or retinal abnormalities that would affect scanning laser polarimetry;
- previous intraocular surgery;
- currently pregnant or nursing women, or women considering pregnancy;
- Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, respiratory disease, or cancer and life expectancy less than one year.
- History of allergy to mannitol.
Sites / Locations
- Singapore Eye Research InstituteRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Copaxone
Placebo
COPAXONE (glatiramer acetate) will be administered as a subcutaneous dose (20mg) once, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
Placebo (buffered normal saline w/v)will be administered as a subcutaneous dose, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.